GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center
The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose
Trial is expected to enroll approximately 40 adult subjects diagnosed with type 2 diabetes
GBS is seeking to support clinical validation of its Saliva Glucose Biosensor through
use of the initial data, anticipated later this summer
The study, Specimen Collection Methodology to Support Subsequent Correlation Analyses of Glucose in Oral Fluids, Capillary, and Venous Blood, is expected to begin enrolling patients in 2Q’22. GBS anticipates initial data will be submitted for publication in 2H‘22.
“We are excited to initiate this clinical study on schedule, an admirable feat given how challenged health systems have been by the protracted COVID-19 pandemic,” said Dr.
GBS will be working with:
Sutter Health, Mills-Peninsula Medical Centerto enroll approximately 40 adult subjects diagnosed with type 2 diabetes in the study. Measures to ensure adequate distribution of age and sex will be taken. Sutter Health, Mills-Peninsula Medical Centerwill also collect and freeze saliva and blood samples for subsequent analysis by other partners.
- Quest Diagnostics® and the
Johns Hopkins Hospital, Department of Pathology, will perform tests on the samples to determine the amount of glucose in oral fluids, venous blood and capillary blood.
- GBS will perform subsequent statistical analyses of the correlation of glucose levels among these sample types.
Dr. Klonoffwill review the results of this analysis.
For more information, please visit GBS.inc or follow
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, GBS Inc.’s ability to develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although
For more information, please contact:
Spiro Sakiris – Chief Financial Officer
Source: GBS, Inc.